The level of ratio between matrix metalloproteinase-1 (MMP-1) and tissue inhibitor matrix metalloproteinase-1 (TIMP-1) after prolotherapy intervention and the functional outcome in patient with frozen shoulder: A randomized controlled trial.
This report has been verified
by one or more authors of the
original publication.
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2024;12(5):12 Medicine (Baltimore) . 2023 Jul 28;102(30):e34356.What this means for my practice?
In patients with chronic FS between the ages of 35 and 70 years, prolotherapy appears to be more effective in increasing the MMP-1/TIMP-1 ratio suggesting it may be better for regeneration of the joint. Both therapies showed good pain reduction, improved ROM, and good functional outcomes. The study was limited by the number of subjects lost to follow-up, the possible influence of the other illness on the inflammatory markers, small sample size and uniform ethnic population preventing generalization of the results. Further research should be undertaken to explore the effectiveness of prolotherapy in different ethnic groups.
Study Summary
51 patients between the ages of 35 and 70 years with chronic frozen shoulder (FS) were included in this retrospective, double blind trial in which patients were randomly allotted to undergo prolotherapy (PT; n=19) or normal saline injections (NS; n=20). The primary outcomes of interest was the change in the ratio of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1). The secondary outcomes of interest included the change in pain, assessed by numeric rating scale (NRS), and function, assessed by range of motion (ROM) and the disability of the arm, shoulder, and hand (DASH) score. All outcomes were measured at baseline and at 6 and 12 weeks. Results reveal a significant improvement in the MMP-1/TIMP-1 ratio in the PT group at 6 and 12 weeks. No significant between-group differences were found in terms of NRS or DASH scores at 6 and 12 weeks. No significant difference was observed between groups with regards to ROM.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
